2009
Hormonal Contraception and Metabolic Outcomes in Women With or at Risk for HIV Infection
Womack JA, Scherzer R, Cole SR, Fennie K, Williams AB, Grey M, Minkoff H, Anastos K, Cohen MH, Tien PC. Hormonal Contraception and Metabolic Outcomes in Women With or at Risk for HIV Infection. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2009, 52: 581-587. PMID: 19950431, PMCID: PMC2886798, DOI: 10.1097/qai.0b013e3181b9e5ee.Peer-Reviewed Original ResearchConceptsCombined Hormonal ContraceptionGreater HOMA-IRNon-HC usersHormonal contraceptionHOMA-IRLow HDLHIV infectionMetabolic outcomesDensity lipoproteinWomen's Interagency HIV StudyHomeostasis model assessment estimateDisorders of glucoseAdverse metabolic outcomesHigh-density lipoproteinLow-density lipoproteinUninfected womenAntiretroviral therapyHigher HDLAdverse outcomesInsulin resistanceContraceptive efficacyHIV StudyReproductive ageCardiovascular diseaseHIV
2008
Hormonal Contraception and HIV‐Positive Women: Metabolic Concerns and Management Strategies
Womack J, Richman S, Tien PC, Grey M, Williams A. Hormonal Contraception and HIV‐Positive Women: Metabolic Concerns and Management Strategies. Journal Of Midwifery & Women's Health 2008, 53: 362-375. PMID: 18586190, PMCID: PMC2776678, DOI: 10.1016/j.jmwh.2008.01.006.Peer-Reviewed Original ResearchConceptsHIV-positive womenMore HIV-positive womenHormonal contraceptionMetabolic dysfunctionMetabolic dysregulationLong-term complicationsPresence of HIVAdditive side effectsHIV seropositivityMetabolic concernsReversible contraceptionSide effectsHIVContraceptionWomenComplicationsDysfunctionDysregulationManagement strategiesClinicians